Stuttgart - Delayed Quote EUR

Axonics Inc (0I3.SG)

61.50

0.00

(0.00%)

At close: 9:08 PM GMT+2

Boston Scientific Announces Results for First Quarter 2024

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million or $0.33 per share (EPS), compared to $300 million or $0.21 per share a year ago, and achieved adjusted3 EPS of $0.56 for

PR Newswire 9 hours ago

BSX

AXNX
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy

Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 26 days ago

AXNX
Axonics Stockholders Approve Merger Agreement with Boston Scientific

IRVINE, Calif., March 22, 2024--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics’ common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independen

Business Wire last month

AXNX
Axonics Provides Update on Inter Partes Review Proceedings

IRVINE, Calif., March 21, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting.

Business Wire last month

AXNX
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

IRVINE, Calif., March 14, 2024--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.

Business Wire last month

AXNX
Axonics Full Year 2023 Earnings: EPS Beats Expectations

Axonics ( NASDAQ:AXNX ) Full Year 2023 Results Key Financial Results Revenue: US$366.4m (up 34% from FY 2022). Net...

Simply Wall St. last month

AXNX
Axonics Responds to ITC Action by Medtronic

IRVINE, Calif., February 29, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware. The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a "patient programmer with automated MRI compatibility verification" for an implantable medical device.

Business Wire last month

AXNX
Axonics Inc (AXNX) Reports Robust Revenue Growth and Margin Expansion in Q4 and FY 2023

Comprehensive Financial Performance Drives Optimism Despite Net Loss for the Fiscal Year

GuruFocus.com last month

AXNX
Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 116.67% and 0.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

AXNX
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results

IRVINE, Calif., February 28, 2024--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2023.

Business Wire last month

AXNX
Insider Sell: Chief Medical Officer Karen Noblett Sells 11,288 Shares of Axonics Inc (AXNX)

On January 31, 2024, Chief Medical Officer Karen Noblett executed a sale of 11,288 shares of Axonics Inc (NASDAQ:AXNX).

GuruFocus.com 2 months ago

AXNX
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for

PR Newswire 2 months ago

BSX

AXNX
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

Here is how Elevance Health (ELV) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

Zacks 3 months ago

ELV

AXNX
Why Axonics Stock Soared Today

The medical device maker agreed to be acquired by Boston Scientific.

Motley Fool 3 months ago

BSX

AXNX
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue

IRVINE, Calif., January 08, 2024--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023.

Business Wire 3 months ago

AXNX
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific

IRVINE, Calif., January 08, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.

Business Wire 3 months ago

BSX

AXNX
Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price is $71 in cash per share, reflecting an equity value of approximately $3.7 billion and an enterprise value of approximately $3.4 billion.1

PR Newswire 3 months ago

BSX

AXNX
Axonics to Present at the J.P. Morgan Healthcare Conference

IRVINE, Calif., December 27, 2023--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024.

Business Wire 3 months ago

AXNX
When Will Axonics, Inc. (NASDAQ:AXNX) Become Profitable?

With the business potentially at an important milestone, we thought we'd take a closer look at Axonics, Inc.'s...

Simply Wall St. 4 months ago

AXNX
Wall Street Analysts Believe Axonics (AXNX) Could Rally 25.1%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 25.1% in Axonics (AXNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 5 months ago

AXNX

Performance Overview

Return	0I3.SG	S&P 500
YTD	+8.85%	+6.33%
1-Year	+16.04%	+22.70%
3-Year	+23.00%	+21.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Axonics Inc (0I3.SG)

Boston Scientific Announces Results for First Quarter 2024

All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy

Axonics Stockholders Approve Merger Agreement with Boston Scientific

Axonics Provides Update on Inter Partes Review Proceedings

Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Axonics Full Year 2023 Earnings: EPS Beats Expectations

Axonics Responds to ITC Action by Medtronic

Axonics Inc (AXNX) Reports Robust Revenue Growth and Margin Expansion in Q4 and FY 2023

Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates

Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Insider Sell: Chief Medical Officer Karen Noblett Sells 11,288 Shares of Axonics Inc (AXNX)

Boston Scientific Announces Results for Fourth Quarter and Full Year 2023

Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

Why Axonics Stock Soared Today

Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue

Axonics Announces Definitive Agreement to be Acquired by Boston Scientific

Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Axonics to Present at the J.P. Morgan Healthcare Conference

When Will Axonics, Inc. (NASDAQ:AXNX) Become Profitable?

Wall Street Analysts Believe Axonics (AXNX) Could Rally 25.1%: Here's is How to Trade

Performance Overview